Fosamprenavir (Lexiva, Telzir)

Published October 30, 2003; Updated May 17, 2012
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-03-08
Selected References
3. Press release: Vertex Reports Preliminary 48-Week Data from Phase III Study of 433908, an Investigational HIV Protease Inhibitor. 7/24/03. http://www.vpharm.com/Pressreleases2003/pr072403.html
4. DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced Subjects with Virological Failure (24 Week Results). 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Abstract 178.
10. Elston RC, Yates P, Tisdale M, Richards N, White S, DeJesus E. GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: A retrospective analysis of virological response based on baseline genotype and phenotype. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoOrB1055.